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Abstract
Health care providers must be equipped to provide appropriate advice to reproductive-aged 
patients for protection against the potentially devastating consequences of prenatal Zika virus 
exposure. The goal of this commentary is to summarize what is known about the safety and 
toxicity of N,N-diethyl-meta-toluamide (DEET) as a topical insect repellant and the pyrethroid 
permethrin for treatment of fabric, endorsed in the fight against Zika virus. Reviews assessing the 
safety and toxicity of DEET conducted by the U.S. Environmental Protection Agency and the 
Canadian Pest Management Regulatory Agency conclude that DEET has low acute toxicity and 
does not appear to pose a significant health concern to humans when used as directed. Some 
experimental animal and limited epidemiologic data suggest that prenatal pyrethroid exposure may 
adversely affect learning and behavior, but this level of evidence pales in comparison to the known 
risks of Zika virus to the fetal brain. The available evidence has led to the strong recommendation 
by the Centers for Disease Control and Prevention for use of these products by pregnant women as 
personal protection against mosquito bites in the fight against Zika virus infection. This message 
has been affirmed by our obstetrics and gynecology professional organizations. Because Zika virus 
is unlikely to be the last disease requiring vector control, those with environmental health expertise 
must continue to join with infectious disease specialists to communicate the potential vulnerability 
of our youngest (fetuses, infants, and young children) to vector-borne disease, both to the disease 
itself and to the strategies employed to mitigate the spread of such disease.
Prenatal Zika virus infection has been linked with devastating consequences for the fetus and 
newborn, including fetal death, neonatal death, microcephaly, central nervous system 
lesions, uteroplacental insufficiency and growth restriction, and hearing loss.1 Obstetrician–
gynecologists must be knowledgeable about appropriate advice to provide reproductive-aged 
patients for protection against this devastating disease. The goal of this commentary is to 
summarize for providers and patients what is known about the safety and toxicity during 
pregnancy of two specific insect repellants, N,N-diethyl-meta-toluamide (DEET) and 
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permethrin. Based on the available evidence, these U.S. Environmental Protection Agency 
(EPA)–approved insect repellants have been strongly recommended for use during 
pregnancy by the Centers for Disease Control and Prevention (CDC) as a key component in 
the multipronged approach for avoiding mosquito bites in the fight against Zika virus 
infection,2 an approach affirmed by our obstetrics and gynecology professional 
organizations.3 We refer readers to two Internet-accessible living documents for further 
details about prenatal Zika virus infection and for up-to-date guidelines regarding 
counseling, screening, and diagnosis of infection during pregnancy.2,3 Recommendations for 
use of insect repellants on infants and young children may differ from those for adults and 
pregnant women, so health care providers and parents should consult the pediatric guidelines 
for the appropriate use of insect repellants in children.4
The biology of the primary mosquito vector transmitting Zika virus, Aedes aegypti, has 
implications for vector control.5 Importantly, Aedes aegypti mosquitoes are quite adaptable 
to human settings and can bite both indoors and outdoors, with a preference for indoor 
biting. Biting can occur throughout the day, and, with enough artificial light, biting can even 
occur at night. In contrast, Anopheles mosquitoes, the vectors that transmit malaria, feed 
from dusk until daybreak. Bednets, which have been a cornerstone of the strategy for 
prevention of malaria transmission, will not be as useful in the fight against the Zika virus. 
Personal protection through repellant use combined with other measures to decrease the 
mosquito population is central to prevention. We turn our attention now to review what is 
known about DEET and permethrin during pregnancy.
DEET
DEET has been marketed as an insect repellant worldwide since the 1950s and is used by an 
estimated 50 to 100 million individuals in the United States yearly.6 DEET previously has 
been recommended by the CDC for use by pregnant women in the United States for 
protection against West Nile virus7 as well as Lyme disease,8 because DEET also repels 
ticks. In head-to-head comparisons against other insect repellants available in the United 
States, DEET products provided the longest protection against mosquito bites, 
outperforming products containing IR3535 (ethyl butylacetylaminoproprionate), citronella, 
lemongrass oil, cedar oil, geranium oil, and peppermint oil.9 Another insecticide alternative 
to DEET is picaridin, although in at least one investigation it was less effective in providing 
protection against Aedes mosquitoes compared with DEET.10 DEET is generally considered 
the most effective insect repellant available on the market, which is why it is specifically 
named in Zika guidelines as the repellant of choice. Although picaridin appears relatively 
nontoxic and safe to use,11 information is less extensive, especially its safety during 
pregnancy.
DEET’s purported mechanism of action is a disturbance in the receptors of the mosquito 
antennae that allow it to locate humans.12 There are more than 200 DEET products available 
on the market in concentrations as high as 100%.13 DEET’s effectiveness increases with 
rising concentration of the chemical but plateaus at a concentration around 50%, rendering 
products with higher concentrations of DEET unlikely or uncertain to offer additional 
benefit.14 Dermal absorption studies using nonpregnant adult volunteers have documented 
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absorption in the range of 5–15%.15 Theoretically, absorption may be higher among 
pregnant women given increased dermal blood flow, but this has not been studied. Exposure 
also could occur by inhalation if the product is aerosolized during application or ingestion 
from food contaminated by hands covered with DEET. After absorption in humans, DEET is 
metabolized by the kidney and undergoes fairly rapid excretion within about 24 hours.13
The safety and toxicity of DEET was reviewed extensively by the EPA in 199816 and 
reaffirmed in 2014.13 The Canadian Pest Management Regulatory Agency also performed a 
thorough review of DEET in 2002.17 These reviews have consistently concluded that DEET 
has low acute toxicity and does not appear to pose a significant health concern to humans 
when used as directed. Most adverse effects described are local skin reactions. A few 
scattered reports of adverse neurologic effects with extremely high exposures, including 
seizures and encephalopathy, have been noted but appear rare and secondary to intentional 
poisoning by ingestion or extraordinarily excessive repeated dermal applications. DEET is 
not considered genotoxic or carcinogenic by the EPA.13 Animal data do not suggest a 
particular vulnerability to the chemical among the young, in contrast to many other 
chemicals that do display age-dependent differential toxicity. The Canadian Pest 
Management Regulatory Agency no longer registers products containing more than 30% 
DEET based on their evaluation of the margins of exposure (the ratio of the estimated dose 
to the no observable adverse level in animal studies).17 The EPA has not been as strict with 
product registrations.
There is an isolated case report describing a child born with craniofacial malformations 
(hypertelorism, poorly developed philtrum, broad nasal bridge) who was subsequently 
diagnosed with developmental delay.18 During the pregnancy, his mother was working in 
Africa and used chloroquine for malaria chemoprophylaxis and applied DEET daily. In 
addition, there is a case–control study reporting an adjusted odds ratio for hypospadias of 
1.81 (95% confidence interval 1.06–3.11) from exposure to unspecified insect repellants 
during pregnancy.19 Exposure was assessed by maternal recall, often several years after the 
incident pregnancy. These very limited reports with considerable limitations are insufficient 
to establish significant concern about the teratogenicity of DEET. Based on more extensive 
available animal data, the EPA has concluded that DEET is neither a reproductive nor a 
developmental toxicant.13,16 Similarly, sources such as REPROTOX20 and the Teratogen 
Information Source21 conclude that there is no demonstrated increased risk of congenital 
anomalies after exposure to DEET from data currently available.
Second- and third-trimester DEET use has been studied in one randomized controlled trial 
conducted among 897 pregnant women in an area with endemic malaria along the Thai-
Myanmar border.22 Women were randomized to apply thanaka, a locally sourced topical 
cosmetic paste, alone or in combination with 1.7 g of DEET at night. Unfortunately, it is 
challenging to compare this dose with standard concentrations in products available in the 
United States. Skin warming as reported by the mothers was more frequent among women 
in the DEET group; other side effects assessed did not differ by group. No significant 
differences were noted between the two groups in birth weight, newborn anthropometrics, a 
newborn neurologic examination, or developmental milestones in the first year of life. 
Exposure to DEET was measured among a subset of patients. None had detectable DEET, 
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suggesting that the women were able to metabolize the repellant without accumulation 
despite daily administration. Cord blood was also collected from 50 newborns in the DEET 
group. In four (8%) of these cord blood samples, DEET was detectable, demonstrating that 
placental transfer occurs. All four children with measurable cord blood DEET had normal 
physical and neurologic examinations at birth and through the first year of life.
To summarize, based on currently available information, DEET appears safe for use 
topically in pregnancy. It is not considered a developmental or reproductive toxicant, and 
there is no indication that the young (eg, fetuses) are more vulnerable. We agree with 
recommendations for its use by pregnant women who must travel to or who live in areas 
where the Zika virus has been reported. Safe use includes application of products at a 
concentration of 30% or less, avoiding products combined with sunscreen, applying 
sunscreen first when required, and not reapplying more frequently than recommended by the 
specific product being applied. Two relevant patient fact sheets, “Insect Repellants” and 
“DEET (N,N-ethyl-m-toluamide) and Pregnancy,” have been created by the Organization of 
Teratology Information Specialists and are available online.23,24
PERMETHRIN
For avoidance of mosquito bites, the CDC also recommends that pregnant women treat 
clothing with the repellant permethrin. It should not be applied directly to the skin.2 
Permethrin is the only repellant currently registered to treat fabric in the United States.25 
Permethrin is also applied as both a residential and commercial insecticide for control of 
mosquito populations within homes, in agricultural fields, and in communities.26 It can both 
repel and kill insects. Permethrin is additionally available as a pharmaceutical in the form of 
topical cream for the treatment of scabies. No increase in the risk of congenital anomalies 
has been noted from the limited data available on topical use as a treatment of scabies.27,28 
The U.S. Food and Drug Administration classifies permethrin cream as class B during 
pregnancy.29 The World Health Organization considers permethrin compatible with 
breastfeeding.30
Permethrin is a pyrethroid, a synthetic compound related to naturally occurring pyrethrins, 
which are derived from the extract of chrysanthemum flower. Naturally occurring pyrethrins 
have some insecticidal activity but become unstable with light exposure and may be more 
likely to cause allergic reactions.26 As a class, pyrethroids are neurotoxicants and work by 
inhibiting sodium channels in the nerve cell.31 Their mechanism of action is negatively 
correlated with temperature, making them particularly toxic to cold-blooded organisms such 
as insects and fish.26 Toxicity to mammals such as humans is considered to be fairly low 
secondary to our higher body temperature, more abundant detoxifying enzymes, and a lower 
sensitivity of the mammalian sodium ion channel to inhibition from pyrethroids.25 
Moreover, absorption is poor from the human gastrointestinal tract, and the liver metabolizes 
it fairly quickly.
For permethrin specifically, absorption after a single application of the cream to the scalp or 
skin is less than 1%, with near-complete elimination of metabolites by 1 week.32,33 Studies 
conducted among military personnel wearing permethrin-treated clothing demonstrate that 
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exposure from chronic daily wear correlates with duration of exposure and is higher than the 
background exposure among the general population.34,35 Nonetheless, calculated daily 
exposures were still lower than exposure from topical pharmaceutical application.26 Mild 
side effects from human exposure to pyrethroids as a class (not permethrin specifically) 
include numbing, tingling, and a burning sensation in the skin. High exposures can lead to 
acute neurotoxicity with symptoms of nausea, vomiting, shortness of breath, and seizures.36 
Pyrethroids are also lipophilic and have the potential to accumulate in the brain and fat and 
be transferred to breast milk.
Unlike DEET, there does appear to be differential toxicity to pyrethroids depending on age, 
with younger mammals potentially more susceptible to side effects.36 Given that the nerve 
cell is the target for pyrethroids, a particular concern is the potential neurotoxicity of 
pyrethroids to the very young. Experimental animal data suggest that prenatal pyrethroid 
exposure may adversely affect learning and behavior, but exposures are much higher in such 
experiments than in typical human exposures and metabolism may be quite different. 
Extrapolation of these results to the human situation is therefore challenging. The potential 
for low-level prenatal or infant exposures in humans to disturb neurodevelopment is an 
emerging area of investigation. One group of researchers found that children in New York 
City exposed to higher levels of piperonyl butoxide, the typical solvent used with pyrethroid 
products, scored lower on the Bayley Mental Development Index at 36 months even after 
adjustment for potential confounders.37 Piperonyl butoxide was specifically chosen as an 
exposure biomarker for permethrin because pyrethroids are notoriously difficult to measure 
in air given their volatility and difficult to measure in plasma given rapid metabolism. The 
appropriate conclusion as to whether the potential neurotoxicity is related to the permethrin 
or to its piperonyl butoxide solvent is not clear, and the potential for developmental toxicity 
after low-level pyrethroid exposure remains uncertain. Furthermore, the applicability of 
studies such as this to exposures from permethrin-treated fabric rather than residential and 
commercial pyrethroid pesticide use is unclear.
DISCUSSION
In light of the extensive neurologic harm that can be caused by prenatal Zika virus infection 
combined with what is known about the safety of DEET and permethrin if used as intended, 
CDC has made strong recommendations for the use of these repellants during pregnancy for 
prevention of Zika virus infection. Unfortunately, personal avoidance measures alone, which 
include application of insect repellants, will not prevent 100% of mosquito bites. Wider 
issues of vector control for Zika prevention will need to be considered by governments and 
affected communities—how and when to recommend larvicide or insecticide spraying and 
which are the most efficacious, safest, and least likely to harm living creatures or accumulate 
in the environment. To the extent that risks from prenatal and early-life exposure to specific 
insecticides remain unclear, additional research should be funded by government and 
nongovernmental organizations.
Vector control is not unique to our time or place. People living in resource-poor countries 
have been grappling with this for years because of malaria and other vector-borne health 
threats. Even when a vaccine becomes available for Zika virus, it is hard to imagine a world 
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free of vector-borne disease. With more than 725,000 human deaths per year, the mosquito 
remains the world’s deadliest animal.38 In this ever-changing world, obstetrician–
gynecologists will continue to field questions from their pregnant patients about vector-
borne disease and the use of insect repellants.
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